Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 7/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22031127 | 0.87 | CDK5 (0.44) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL24044235 | 0.87 | CDK5 (0.44) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL22031130 | 0.82 | CDK5 (0.39) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL20557968 | 0.80 | CDK5 (0.42) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL9481298 | 0.80 | SMN1; SMN2 (0.47) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL7494013 | 0.80 | HDAC3 (0.45) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL2600848 | 0.79 | PI4KB (0.42) | PI4KBCA1CA2SCN9ALCK | |
| SCHEMBL21705628 | 0.79 | LCK (0.41) | PI4KBCA1CA2SCN9ASREBF2 | |
| SCHEMBL2642567 | 0.79 | L3MBTL1 (0.43) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL5988707 | 0.78 | ABCB1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630111-B1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11046694-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200165251-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046694-B2 | Compounds and methods for treating bacterial infections | MRPL21, CFTR, C5 | CDK5 4226/4885CDK5R1 2362/4885CCNA2 3700/4885 |
| US-20200165251-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MRPL21, CFTR, C5 | CDK5 4226/4885CDK5R1 2362/4885CCNA2 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.